$7.49+0.40 (+5.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Kura Oncology (KURA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
4 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue history is too short to read a growth trend, net margin −412.9%. Worth your attention in FY25: Share count (+32.1%) and Capex step-up ($6.6M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲25.2%
67.5
FY21→FY25CAGR —
Net income ($M)▼60.2%
−278.7
FY21→FY25CAGR —
Free cash flow ($M)—
−70.7
capex stepped upCAGR —
Diluted EPS▼57.4%
−3.18
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+32.1%
66.4mn → 87.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$6.6M
▲1306% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-413¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -412.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 79,314.0 | 67,482.0 | 53,883.0 | 0.0 | 0.0 | 0.0 | ▲25.2% | — |
Cost of revenue | 933.0 | 57.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 78,381.0 | 67,425.0 | —A | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 258,440.0 | 251,074.0 | 169,967.0 | 115,235.0 | 92,812.0 | 84,721.0 | ▲47.7% | +31.2% |
Selling, general & admin | 132,692.0 | 119,982.0 | 77,111.0 | 50,569.0 | 47,053.0 | 46,537.0 | ▲55.6% | +26.7% |
Total operating expenses | 391,132.0 | 371,056.0 | 247,078.0 | 165,804.0 | 139,865.0 | 131,258.0 | ▲50.2% | +29.7% |
Operating incomefeeds ROC rank | −312,751.0 | −303,631.0 | −193,195.0 | −165,804.0 | −139,865.0 | −131,258.0 | ▼57.2% | — |
Other income, net | 19,961.0 | 25,262.0 | 21,230.0 | 13,173.0 | 4,025.0 | 792.0 | — | — |
Pretax income | −292,790.0 | −278,369.0 | −171,965.0 | −152,631.0 | −135,840.0 | −130,466.0 | ▼61.9% | — |
Income tax | 84.0 | 297.0 | 2,018.0 | 0.0 | 0.0 | — | ▼85.3% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −292,874.0 | −278,666.0 | −173,983.0 | −152,631.0 | −135,840.0 | −130,466.0 | ▼60.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.30 | −3.18 | −2.02 | −2.08 | −2.03 | −1.97 | ▼57.4% | — |
Diluted shares (mn) | 89.82 | 87.68 | 86.16 | 73.23 | 66.99 | 66.35 | ▲1.8% | +7.2% |
| Margins | ||||||||
Gross margin97th pct in Healthcare | 98.8% | 99.9% | —A | — | — | — | — | — |
Operating margin | −394.3% | −449.9% | −358.5% | — | — | — | ▼91.4pp | — |
Net margin5th pct in Healthcare | −369.3% | −412.9% | −322.9% | — | — | — | ▼90.1pp | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Kura Oncology's revenue last fiscal year?
Kura Oncology reported revenue of $67.5M in fiscal 2025, up 25.2% from fiscal 2024.
What was Kura Oncology's net income?
Kura Oncology reported net income of −$278.7M in fiscal 2025, a net margin of −412.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

